SLIT Cost: How Sublingual Immunotherapy Is Billed and Coded

Compounded allergy drops are billed directly to you as a self-pay item, not submitted to insurance. Because the sublingual route for these compounded multi-allergen extracts is off-label, there is no recognized immunotherapy supply code for them, so a payer has nothing to adjudicate. Telehealth providers typically charge a flat monthly subscription, around $99 self-pay, that bundles the extract and shipping. What can still bill to insurance is the separate clinical work: the allergy test and the prescribing visit are medical services that may be coded to your medical benefits, though they often apply to your deductible. The drops themselves remain a predictable cash expense, and they are HSA/FSA-eligible.

Insurance reimbursement relies on standardized codes that map a product or service to a covered benefit. FDA-approved drugs carry National Drug Codes, and established procedures like subcutaneous immunotherapy have their own medical codes. Compounded sublingual drops fall outside both systems: they are a prescriber-directed, off-label preparation rather than a finished FDA-approved drug, and the sublingual immunotherapy supply has no dedicated code for payers to process. Without a recognized code, private insurance, Medicare, and Medicaid generally will not pay a claim, so the extract is self-pay. The clinical evaluation behind the prescription can still be coded as a medical service, which is why only that component sometimes bills to insurance.

Yes. FDA-approved SLIT tablets such as Grastek, Oralair, Ragwitek, and Odactra are finished prescription drugs with their own National Drug Codes, so a pharmacy adjudicates them against your plan just like any other medication. If the tablet is on your formulary, you pay a copay set by its tier; some plans require prior authorization first. If it is not covered, you pay the cash drug price, which can be substantial. This pharmacy-benefit pathway is the main billing difference from compounded drops, which have no such code and are self-pay. Tablets target a single allergen, so a multi-allergic patient may need more than one product, affecting both cost and coverage decisions.

Often yes, even when the drops do not. The diagnostic evaluation, including allergy testing and the prescribing visit, is a medical service that providers typically code under standard evaluation-and-management or allergy-testing codes. Those claims may be submitted to your medical benefits, though they commonly apply to your deductible before the plan pays. This is why a telehealth program can advertise a lower insured rate: the clinical component is billable, while the compounded extract is not. Confirm with your provider exactly which line items are submitted to insurance and which are self-pay, since the split between the billable evaluation and the self-pay drops determines your real out-of-pocket cost.

Yes. HSA and FSA eligibility is governed by IRS rules on qualified medical expenses, not by whether an insurer reimburses a claim. Because compounded allergy drops are a provider-directed treatment for an allergic condition, they qualify under IRS Publication 502, so you can pay with pre-tax HSA or FSA dollars even though the drops are off-label and not insurance-covered. Pay with the account debit card or submit receipts for reimbursement, and keep provider documentation in case your administrator requests substantiation. The associated testing and follow-up visits generally qualify as well. Using pre-tax funds effectively discounts the self-pay cost by your marginal tax rate, which is the most reliable saving for off-label drops.